To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Concurrent Medication: Allowed:

• Topical antifungal therapy.

Patient must have:

• Newly diagnosed clinical and histological hairy leukoplakia.
• Positive HIV antibody by licensed ELISA or Western blot.

Exclusion Criteria

Co-existing Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.

Concurrent Medication: Excluded within 2 weeks of study entry:

• Systemic antifungal treatment.
• Excluded within 6 weeks of study entry:
• Immunomodulators.
• Systemic antiviral treatment.

Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.

Prior Medication: Excluded within 2 weeks of study entry:

• Systemic antifungal.
• Excluded within 6 weeks of study entry:
• Immunomodulators.
• Systemic antiviral treatment.
• Excluded within 8 weeks of study entry:
• Zidovudine (AZT) or other antiretroviral therapy.